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BY-NC-ND license (http://creativecomBackground/purpose: To investigate the natural history of renal cell carcinoma (RCC) with de-
layed treatment and to immunohistochemically analyze the correlation between some bio-
markers and the growth rate of RCC.
Methods: We reviewed our institutional databases to identify renal tumors which were
confirmed to be RCC by delayed surgical treatment after at least 12 months of active surveil-
lance (AS). Growth rate was defined as the average growth rate of the maximal diameter on
computed tomography or magnetic resonance imaging. The clinicopathological characteristics
and immunohistochemical biomarkers (Ki-67, p53, bcl-2, and vascular endothelial growth fac-
tor) were analyzed the correlation with the growth rate of RCC.
Results: We identified 45 RCCs from 45 patients. The mean patient age was 54 years (range,
26e78 years). The mean tumor size increased from 2.39 cm (range, 0.10e6.70 cm) at presen-
tation to 4.54 cm (range, 1.40e11.80 cm) after a mean time of 45.4 months (range, 12e155
months) of AS. The mean growth rate was 0.79 cm/y (range, 0.10e4.74 cm), and 36 (80.0%)
tumors presented a growth rate  1.00 cm/y. Clear cell RCC had a trend of growing faster
than other histological subtypes. Pathological grade was significantly correlated with the
growth rate of RCC (p Z 0.043). High positive ratio of Ki-67 (r Z 0.351, p Z 0.018) and being
p53 positive (p Z 0.019) were significantly correlated to the fast growth rate of RCC.ave no conflicts of interest relevant to this article.
t of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Uro-
ku Street, Xicheng District, Beijing 100034, China.
.com (X. Li), zhouliqunmail@sina.com (L. Zhou).
.
5.05.003
n Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC
mons.org/licenses/by-nc-nd/4.0/).
464 L. Zhang et al.Conclusion: In general, RCCs under AS are slow growing with a wide variation of growth rate,
with a portion of RCCs presenting rapid growth kinetics. RCC with rapid growth during AS is
characterized by a high histological grade, high positive ratio of Ki-67, and being p53 positive.
Copyright ª 2015, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
A dramatic increase of incidentally found small renal
masses has been observed with the widespread use of
modern imaging techniques.1 Surgical excision is still the
standard treatment for these localized renal tumors.
However, a number of patients with a high risk of morbidity
and mortality or limited life expectancy choose active
surveillance (AS) instead of immediate surgeries. AS pro-
vides a unique opportunity to observe the natural history of
the renal cell carcinoma (RCC), as most tumors are surgi-
cally excised soon after diagnosis. Previous studies con-
cerning AS demonstrated that small renal tumors grew
slowly and seldom metastasized.2e23 In most of these
studies, lack of pathological diagnosis was a common limi-
tation, even a considerable portion of the tumors with
pathological results were not RCC. Hence, the growth ki-
netics and natural history of RCC have not been well
characterized.
To understand the growth kinetics of RCC fully, a few
studies have evaluated the correlation between the
immunohistochemical biomarkers and the growth rate of
RCCs.3e5 However, all the available researches included
small sample sizes and short follow-up periods, so no
consensus has been reached. The investigations regarding
the correlation between immunohistochemical biomarkers
and the growth rate of RCC are far from sufficient.
Our previous study demonstrated that RCCs were found
to be slow growing in patients with delayed treatment,
however, progression in stages was presented in some
RCCs.2 In the current study, we expanded the sample size
to further examine the growth kinetics of RCC and its cor-
relation with clinical and pathological characteristics. In
addition, we selected four biomarkers, Ki-67, p53, vascular
endothelial growth factor (VEGF), and bcl-2, which were
considered prognostic factors of RCCs in previous stud-
ies,24e26 and immunohistochemically analyzed whether
they were involved in the growth of RCCs with delayed
treatment.
Materials and methods
We reviewed the kidney cancer databases at the Institute
of Urology, Peking University First Hospital, Beijing, China
to identify renal tumors for which AS was performed for at
least 12 months between January 1990 and July 2012. A
total of 60 patients with renal tumors under AS for > 12
months were identified from 2180 renal tumor cases. Pa-
tients who did not receive delayed surgical treatment were
excluded. Finally, 45 renal tumors from 45 patients were
enrolled. During the period of AS, computed tomography(CT) or magnetic resonance imaging (MRI) was performed
every 6 months or less. Where possible, the measurement
was performed based on the same modality. Because of
tumor growth, obvious enhancing on CT, or metastatic le-
sions, delayed surgical intervention was performed on all
patients at Peking University First Hospital after a mean
duration of 45 months of AS. The pathological results
confirmed RCC for all tumors. Growth rate was defined as
the average growth rate of the maximal diameter on a se-
ries of 2-dimensional images. Histological classification was
determined using the Heidelberg typing system.27 Tumor
stage was assessed according to the 2002 American Joint
Committee on Cancer TNM staging system.28 Tumor grading
was performed according to the Fuhrman grade system.29
Paraffin-embedded sections were stained using a
ChemMate EnVision Detection Kit (Genetic Technology,
Shanghai, China). The antibodies (Genetic Technology,
Shanghai, China) used in this study included bcl-2 and p53,
VEGF, and Ki-67. Paraffin sections were deparaffinized and
then dipped into phosphate buffer solution for 5 minutes
three times. Then, sections were incubated in primary
antibody for 30 minutes at room temperature and another 4
hours at 4C. The Envision method was used for immuno-
histochemical staining. Slides were exposed to dia-
minobenzidine for 5 minutes three times. After
immunostaining, the sections were counterstained with
hematoxylin, coverslipped, and sealed. Phosphate buffer
solution was used as a negative control of the first antibody
for each group.
The expression levels of bcl-2 and VEGF were detected
based on the intensity of staining and the percentage of
positive cells. The intensity of staining was scored as fol-
lows: unstained Z 0 points; light brown color Z 1 point;
brown Z 2 points; and deep brown color Z 3 points. The
percentage of positive cells was scored as follows: < 5%Z 0
points; 5e10% Z 1 point; 10e50% Z 2 points; and >
50% Z 3 points. The sum of the two items was scored as
follows: 0 points Z negative; 1e3 points Z weakly posi-
tive; and 4e6 points Z strongly positive. More than 10% of
the nucleus stained was the positive standard for p53. Ki-67
was recorded as the Ki-67 labeling index, which was defined
as the proportion of Ki-67-positive cells per 1000 cells in 10
representative Ki-67-positive fields. All sections were
separately reviewed by two urological pathologists who
were blinded to the patients’ personal data. If the opinions
were inconsistent, the sections were reviewed by the two
pathologists together to reach an agreement.
For better knowledge of the natural history and growth
kinetics of renal masses, we also reviewed published series
regarding AS of renal masses and made a pooled analysis. In
addition, through the pooled analysis, we wanted to know
the metastatic rate during AS and the rate of pathologically









































ccRCC Z clear cell renal cell carcinoma; gCC Z granular cell
carcinoma; MTSCCa Z mucinous tubular and spindle cell car-
cinoma; pRCC Z papillary renal cell carcinoma.
Immunohistochemical analysis of growth rate of RCC 465confirmed RCC among the renal masses that underwent AS.
As all the cases were proven RCC in the current study,
through comparing the results of AS from this study with the
results of the pooled analysis, we might further understand
the characteristics of RCCs natural history.
Statistical analysis
The Chi-square test was used to test the distribution of
categorical variables. The correlations between growth
rate and Ki-67, and between initial size and growth rate
were assessed by calculating Pearson’s correlation coeffi-
cient. The ManneWhitney U test or the Kruskal-Wallis H
test was used for continuous variables. SPSS version14.0
software package (SPSS Inc., Chicago, IL, USA) was used for
data processing. A p value < 0.05 was considered statisti-
cally significant.
Results
Patient characteristics and outcome of AS
We identified 45 renal tumors from 45 patients who were
treated by delayed intervention after at least 12 months of
AS. Most tumors (40/45, 88.9%) were asymptomatic and
diagnosed incidentally during the imaging procedures for
physical examination; the other cases were diagnosed with
complaint of flank pain or occasional hematuria. The rea-
sons for no immediate intervention included patient pref-
erence (31/45, 68.9%), considered benign diagnosis at
presentation (10/45, 22.2%), existence of bilateral disease
(2/45, 4.4%), and concomitant malignancy (2/45, 6.3%).
Patient demographics, pathological features, and growth
rates of tumors are summarized in Table 1. The majority of
patients were men (37/45, 82.2%). The mean patient age
was 54 years (range, 26e78 years). The mean tumor size
increased from 2.39 cm (range, 0.10e6.70 cm) at presen-
tation to 4.54 cm (range, 1.40e11.80 cm) after a mean
duration of 45.4 months (range, 12e155 months) AS. Most
of the tumors (38/45, 84.4%) were  4 cm at presentation.
Stage progression was documented in 16 tumors: 11 tumors
progressed from T1a to T1b, four tumors progressed from
T1a to T2, and one tumor progressed from T1b to T2. pT
stage was in concordance with cT stage at operation for all
tumors. During AS, only one patient presented with a
biopsy-proven metastasis RCC in the lung at the 155th
month of AS, the primary tumor was 1.6 cm in diameter at
presentation. Interestingly, this tumor did not grow fast,
the average growth rate was 0.20 cm/y.
Surgical intervention was performed because of tumor
growth, presence of obvious enhancing on CT, or metastatic
lesion (palliative excision of primary lesion). Twenty-three
tumors (51.1%) were treated with radical nephrectomy,
while the other 22 tumors (48.9%) were treated with partial
nephrectomy. The pathological results confirmed RCC in all
45 cases. Thirty-nine tumors (86.7%) were clear cell carci-
noma, four tumors (8.9%) were papillary cell carcinoma,
one tumor (2.2%) was mucinous tubular and spindle cell
carcinoma, and one tumor (2.2%) was granular cell carci-
noma. Nine tumors (20%) were Grade 1, 29 tumors (64.4%)
were Grade 2, and seven tumors (15.6%) were Grade 3.Growth kinetics of RCC
The mean growth rate was 0.79 cm/y (range,
0.10e4.74 cm). Most of these tumors grew slowly, 36
(80.0%) tumors presented a growth rate  1.00 cm/y, while
nine (20.0%) tumors had a growth rate > 1.00 cm/y. Initial
size, sex, and age were not correlated to the growth rate of
RCC. The results of growth rate based on pathological
characteristics were summarized in Table 2. Given the
limitation of the sample size, we did not make a compari-
son between different histological subtypes. However,
clear cell RCC (ccRCC), with a mean growth rate of
0.82 cm/y, had a trend of growing faster than other histo-
logical subtypes. For all tumors, tumors with high grades
























Histological grade of all
cases
G1 (n Z 9) 0.34/0.30 (0.10
e0.63)
G2 (n Z 29) 0.74/0.63 (0.11
e2.31)
0.043*
G3 (n Z 7) 1.56/0.60 (0.20
e4.74)
Histological grade of clear cell RCC
G1 (n Z 8) 0.34/0.25 (0.10
e0.63)
G2 (n Z 26) 0.71/0.63 (0.11
e2.31)
0.030*
G3 (n Z 5) 1.79/0.75 (0.26
e4.74)
*The significance is p<0.05.
466 L. Zhang et al.grew faster than tumors with low grades (pZ 0.043). After
rerunning the data by focusing on ccRCC, it was also
confirmed that high grade tumors grew faster than low
grade tumors and the difference was more significant
(p Z 0.030).
Pooled analysis of published series on the natural
history of renal masses
The pooled analysis revealed a total of 1171 patients with
1271 renal tumors (Table 3). Of the 1271 renal tumors, only
444 (34.9%) had pathological results, and 380 (29.9%) were
RCC. Collectively, the mean age was 69.5 years (range,
52.2e80.4 years), the mean growth rate was 0.33 cm/y
(0.06e0.8 cm), and the mean duration of AS was 34.6
months (range, 12.6e91.5 months). Nineteen (1.6%) pa-
tients developed metastatic disease during AS.
Immunohistochemical analysis according to growth
rate, tumor initial size, and histological grade
Representative immunostaining for Ki-67, p53, bcl-2, and
VEGF are shown in Figure 1. The Ki-67 labeling index
(Figure 2), which ranged from 0 to 70, was correlated with
the growth rate of RCC (r Z 0.351, p Z 0.018). RCCs that
were p53 positive had a faster growth pattern than RCCsthat were p53 negative (0.97 cm/y vs. 0.41 cm/y,
p Z 0.019). No negative staining for bcl-2 or VEGF was
observed. However, bcl-2 and VEGF were not correlated
with the growth rate of RCC. No correlation was observed
between initial tumor size and the expression of Ki-67, p53,
bcl-2, and VEGF. Tumors of a high grade had more chance of
being p53 positive compared with tumors of a low grade
(pZ 0.006), while the expression of Ki-67, bcl-2, and VEGF
were not correlated to tumor grade. There was no signifi-
cant correlation between any two of the biomarkers bcl-2,
VEGF, p53, and Ki-67.Discussion
For renal masses, AS with delayed treatment until pro-
gression is now gradually accepted especially for patients
with a high risk of surgery and limited life-expectancy. A
number of published series on AS of small renal masses
provide the unique opportunity to assess the growth of RCC.
A meta-analysis with 234 renal tumors revealed a mean
growth rate of 0.28 cm/y, the tumors pathologically
confirmed RCC had a higher growth rate of 0.4 cm/y.6 RCC
may have relatively aggressive growth potential compared
with other benign renal tumors. In addition, there is no
curative salvage therapy for metastatic RCCs at present.
Compared with assessing the growth of renal masses in
general, it will be more beneficial to focus on the growth
kinetics of RCC.
We reviewed published series regarding AS of renal
masses and made a pooled analysis (Table 3). The pooled
analysis showed renal tumors during AS had slow growth
kinetics and a low rate of metastasis. Of the 1271 analyz-
able lesions, only 444 (34.9%) had pathological results, and
380 (29.9%) were RCC. Apparently, the most common limi-
tation of these reports was lack of pathological results. The
kinetics of RCC could not be correctly reflected by the
pooled analysis.
In the current study, all the tumors finally received
delayed surgical excision after a mean duration of 45
months of AS, and were pathologically confirmed as RCC.
Compared with other series, these tumors had a similar
initial tumor size (mean, 2.39 cm), a relatively longer
period of AS, and a similar metastasis rate during AS (2.2%).
Our results also revealed most of these RCCs were slow
growing, 36 of the 45 tumors (80%) had a growth rate under
1.00 cm/y. However, a wide variation of the growth rate
was observed; the fastest growth rate was 47 times faster
than the lowest one. In comparison with other series, this
cohort had a relative rapid growth rate. We explain the
phenomenon through the presence of non-RCC pathologies,
elder age, and the follow up period not being long enough
until delayed treatment in the other series. Jewett et al7
demonstrated that there was no difference of the
average growth rate between the biopsy-proven RCCs and
benign tumors. However, most of these RCCs were not
followed up long enough until delayed treatment. Our
previous study indicated the growth of RCCs might accel-
erate along with the continuation of AS.30 So the growth
kinetics and natural history of RCC might be misjudged. We
speculate that the growth rate of RCC is slow and even
comparable to the growth rate of benign tumors at the
















Fujimoto et al3 1995 6/6 59.7 2.47 24 0.47 0 (0) 5/5
Bosniak et al9 1995 37/40 65.5 1.73 39 0.36 0 (0) 22/26
Oda et al4 2003 16/16 54* 2.0* 25 0.54* 0 (0) 16/16
Volpe et al10 2004 29/32 71* 2.48 27.9 0.1 0 (0) 8/9
Wehle et al11 2004 29/29 70 1.83 32 0.12 0 (0) 3/4
Kato et al5 2004 18/18 56.5 2.0 27 0.42 0 (0) 18/18
Lamb et al12 2004 36/36 76.1 7.2 27.7 0.39 1 (2.8) 23/23
Chawla et al6 2006 49/61 71 2.97 36 0.2 1 (1.6) 16/21
Abou Youssif et al13 2007 35/44 71.8 2.2 47.6 0.21 2 (5.7) 6/8
Kouba et al8 2007 43/46 67 2.92 32.8 0.7 0 (0) 12/14
Siu et al14 2007 41/47 68 2.0 29 0.27 1 (2.4) 10/16
Fernando et al15 2007 13/13 80.4 5.01 38.38 0.17 1 (7.7) 0
Matsuzaki et al16 2007 15/15 67 2.2 38 0.06 0 (0) 3/3
Lee et al17 2008 30/30 65.5 2.6 12.6 0.59 3 (10.0) 30/30
Beisland et al18 2009 63/65 76.3 4.3 33 0.66 2 (3.2) 15/18
Crispen et al19 2009 154/173 69 2.45 31 0.285 2 (1.3) 52/61
Rosales et al20 2010 212/223 71* 2.8* 35* 0.34* 4 (1.9) 32/40
Hwang et al21 2010 56/58 64.3 2.1 22 0.21 0 (0) 10/15
Jewett et al7 2011 127/151 73 2.1 28 0.13 1 (0.7) 37/46
Li et al2 2012 32/32 52.2 2.14 46 0.8 0 (0) 32/32
Mehrazin et al22 2014 68/72 68.9 5.3 38.9 0.44 0 (0) 16/23
Brunocilla et al23 2014 62/64 75 2.0 91.5 0.4 1 (1.6) 14/16
Total 1171/
1271
69.5 2.82 34.6 0.33 19 (1.6) 380/444
* Median.
MTD Z maximal tumor diameter; RCC Z renal cell carcinoma.
Immunohistochemical analysis of growth rate of RCC 467early stage of natural history, but along with the continu-
ation of AS, it is not surprising that the malignancy of RCC in
terms of growth rate will show up finally. Our results might
more correctly reflect the potential malignancy of RCC in
the aspect of growth rate.
Up to now, there is no definite prognostics factor of
progression of renal tumors under AS. Previous studies
demonstrated potential predictors of subsequent tumor
growth including initial tumor size, sex, age, and patho-
logical characteristics.8,9 By contrast, the initial tumor size,
sex, and age were not correlated with the growth rate of
RCC in this cohort. The current study indicated that ccRCC
had a trend of growing faster than other histological sub-
types. More non-ccRCC histological subtypes of RCC are
needed to examine the trend in further studies. RCCs with a
high grade had a trend of growing faster than those with a
low grade (pZ 0.043). When focusing the histological type
on ccRCC, we did find that ccRCCs with a high grade grew
faster than ccRCCs with a low grade and the difference was
more significant (p Z 0.030). It might make more sense to
discuss the correlation between grade and the growth rate
of RCC based on a certain histological subtype.
The growth rate of renal tumors under AS is various and
not well predicted by clinical and radiographic factors,
while immunohistochemistry has an advantage of exploring
the nature of tumor growth through assessing the expres-
sion of biomarkers that reflect cell proliferation, apoptosis,
angiogenesis, and so on. To the best of our knowledge, onlythree studies made a immunohistochemical analysis using
surgical samples of RCCs which were treated by a period of
AS initially, and evaluated the correlation between the
expression of immunohistochemical biomarkers and the
growth rate of RCCs.3e5 As the immunohistochemical
analysis was not performed at the beginning of AS, so what
they did may not reflect the prediction role of the bio-
markers in the aspect of growth rate. However, they still
provided valuable features of immunohistochemical bio-
markers for RCCs with aggressive growth rates. In these
studies, no consensus has been reached. The small sample
size and short follow up period limited the strength of these
studies. In the current study, we present an immunohisto-
chemical analysis with a relatively larger sample size and
longer follow up of AS compared with previous studies.
Ki-67 is considered a reliable marker of active cell pro-
liferation. The correlation between Ki-67 and the growth
rate of RCC is controversial. Kato et al5 found the growth
rate of RCC and the Ki-67 positive ratio were not corre-
lated. Oda et al4 discovered the Ki-67 labeling index tended
to increase as the growth rate of RCC increased, but the
correlation was not significant. In contrast with previous
studies, a significant correlation between the Ki-67 labeling
index and the growth rate of RCC was found in the current
study. RCCs with rapid growth rate might present higher Ki-
67 expression than RCCs with a slow growth rate. This
discrepancy could be explained by the small sample size
and short period of follow up in these studies.
Figure 1 Immunostaining of markers in renal cell carcinoma.
Original magnification:  400. (A) High-level staining for bio-
markers; (B) negative (Ki-67, p53) or low-level [bcl-2, vascular
endothelial growth factor (VEGF)] immunostaining for
biomarkers.
468 L. Zhang et al.p53, bcl-2, and VEGF were deemed to have a correlation
with the survival of RCC.25,26 To our knowledge, our expe-
rience provided initial evaluation of the correlation be-
tween these biomarkers and the growth rate of RCC. OurFigure 2 The growth rates of renal cell carcinoma and Ki-67
labeling index. The correlation coefficient was 0.351
(p Z 0.018).results showed that p53 was correlated with the growth
rate of RCC, while bcl-2 and VEGF were not. RCCs with
rapid growth have more chance of being p53 positive than
RCCs with a slow growth rate. As the limitation of retro-
spective design and sample size, prospective studies with a
larger sample size are required to examine these results in
the current study.Conclusion
In general, RCCs are slow growing with a wide variation of
growth rate, some of them present rapid growth rates,
which should be considered before AS. RCC with rapid
growth during AS is characterized by a high histological
grade, high positive ratio of Ki-67, and is p53 positive. This
is helpful for selecting optimal RCCs for AS. Before the
appearance of definite predictors of the progression of
RCC, more attention should be given to the natural history
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